JP2022019973A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022019973A5 JP2022019973A5 JP2021197319A JP2021197319A JP2022019973A5 JP 2022019973 A5 JP2022019973 A5 JP 2022019973A5 JP 2021197319 A JP2021197319 A JP 2021197319A JP 2021197319 A JP2021197319 A JP 2021197319A JP 2022019973 A5 JP2022019973 A5 JP 2022019973A5
- Authority
- JP
- Japan
- Prior art keywords
- activator
- manganese
- pharmaceutically acceptable
- acceptable salt
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012190 activator Substances 0.000 claims 24
- 239000003814 drug Substances 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 10
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 6
- 239000013543 active substance Substances 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- SQKUFYLUXROIFM-UHFFFAOYSA-N 2-[2-[carboxymethyl-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methyl]amino]ethyl-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methyl]amino]acetic acid Chemical compound CC1=NC=C(COP(O)(O)=O)C(CN(CCN(CC(O)=O)CC=2C(=C(C)N=CC=2COP(O)(O)=O)O)CC(O)=O)=C1O SQKUFYLUXROIFM-UHFFFAOYSA-N 0.000 claims 3
- 208000007788 Acute Liver Failure Diseases 0.000 claims 3
- 206010000804 Acute hepatic failure Diseases 0.000 claims 3
- -1 DPDP compound Chemical class 0.000 claims 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 3
- 231100000836 acute liver failure Toxicity 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 229910052748 manganese Inorganic materials 0.000 claims 3
- 239000011572 manganese Substances 0.000 claims 3
- 229960005489 paracetamol Drugs 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 229940127557 pharmaceutical product Drugs 0.000 claims 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 2
- 229960004308 acetylcysteine Drugs 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- UMRUNOIJZLCTGG-UHFFFAOYSA-N calcium;manganese Chemical compound [Ca+2].[Mn].[Mn].[Mn].[Mn] UMRUNOIJZLCTGG-UHFFFAOYSA-N 0.000 claims 2
- JFVHALAXWREODT-UHFFFAOYSA-N C(C=1C(CO)=CN=C(C)C1O)NCCN.[Mn] Chemical compound C(C=1C(CO)=CN=C(C)C1O)NCCN.[Mn] JFVHALAXWREODT-UHFFFAOYSA-N 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 150000004696 coordination complex Chemical class 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims 1
- 229960001327 pyridoxal phosphate Drugs 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277232P | 2016-01-11 | 2016-01-11 | |
| US62/277,232 | 2016-01-11 | ||
| US201662361605P | 2016-07-13 | 2016-07-13 | |
| US62/361,605 | 2016-07-13 | ||
| PCT/IB2017/050115 WO2017122120A1 (en) | 2016-01-11 | 2017-01-10 | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
| JP2018555315A JP7311267B2 (ja) | 2016-01-11 | 2017-01-10 | 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555315A Division JP7311267B2 (ja) | 2016-01-11 | 2017-01-10 | 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022019973A JP2022019973A (ja) | 2022-01-27 |
| JP2022019973A5 true JP2022019973A5 (OSRAM) | 2022-02-03 |
| JP7374163B2 JP7374163B2 (ja) | 2023-11-06 |
Family
ID=57909814
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555315A Active JP7311267B2 (ja) | 2016-01-11 | 2017-01-10 | 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 |
| JP2021197319A Active JP7374163B2 (ja) | 2016-01-11 | 2021-12-03 | 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555315A Active JP7311267B2 (ja) | 2016-01-11 | 2017-01-10 | 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11260060B2 (OSRAM) |
| EP (2) | EP3842040B1 (OSRAM) |
| JP (2) | JP7311267B2 (OSRAM) |
| CN (1) | CN108601757A (OSRAM) |
| AU (1) | AU2017208123B2 (OSRAM) |
| CA (1) | CA3010915C (OSRAM) |
| RU (1) | RU2018128793A (OSRAM) |
| WO (1) | WO2017122120A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017208123B2 (en) * | 2016-01-11 | 2022-04-21 | Egetis Therapeutics Ab | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
| AU2018326705A1 (en) | 2017-08-30 | 2020-03-05 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
| RU2693677C1 (ru) * | 2018-10-15 | 2019-07-03 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ гемокоррекции при лечении печеночной недостаточности |
| US20220211780A1 (en) * | 2019-05-21 | 2022-07-07 | Pendulum Therapeutics, Inc. | Methods And Compositions For Treating Liver Disorders |
| WO2022269026A1 (en) | 2021-06-25 | 2022-12-29 | Forschungsgesellschaft Für Arbeitsphysiologie Und Arbeitsschutz E. V. | Treating acetaminophen overdose |
| WO2024095178A1 (en) | 2022-11-01 | 2024-05-10 | Janssen Pharmaceutica Nv | Thrombopoietin mimetic for use in the treatment of acute liver failure |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566401B2 (en) | 2001-03-30 | 2003-05-20 | The Board Of Trustees Of The Leland Stanford Junior University | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity |
| FR2823977B1 (fr) | 2001-04-26 | 2006-12-01 | Univ Rene Descartes | Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif |
| US20050070607A1 (en) | 2003-08-19 | 2005-03-31 | James Andrus | N-acetylcysteine compositions and methods for the treatment and prevention of cysteine/glutathione deficiency in diseases and conditions |
| US20090234011A1 (en) | 2005-04-21 | 2009-09-17 | Goldstein Glenn A | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress |
| US20100099762A1 (en) | 2006-10-23 | 2010-04-22 | The Mental Health Research Institute Of Victoria | Combination therapy |
| US20080139654A1 (en) * | 2006-12-09 | 2008-06-12 | Eric Mott Soderling | Acetaminophen compositions having minimized side effects including reduced hepatotoxicity |
| CN105688215A (zh) | 2009-07-06 | 2016-06-22 | 普莱制药公司 | 利用锰配合物化合物与所述化合物之非锰配合物形式的组合的药物组合物和治疗方法 |
| CA2862736C (en) * | 2012-01-05 | 2020-09-08 | Pledpharma Ab | Mixed metal complexes and methods |
| US20140178358A1 (en) * | 2012-12-21 | 2014-06-26 | The United States of America as represented by the Secretary of Department of Health and Human Servi | Means and Methods to Diagnose Liver Toxicity using Putrescine as Biomarker |
| AU2017208123B2 (en) | 2016-01-11 | 2022-04-21 | Egetis Therapeutics Ab | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
-
2017
- 2017-01-10 AU AU2017208123A patent/AU2017208123B2/en active Active
- 2017-01-10 RU RU2018128793A patent/RU2018128793A/ru unknown
- 2017-01-10 WO PCT/IB2017/050115 patent/WO2017122120A1/en not_active Ceased
- 2017-01-10 EP EP21158979.1A patent/EP3842040B1/en active Active
- 2017-01-10 CN CN201780006292.1A patent/CN108601757A/zh active Pending
- 2017-01-10 CA CA3010915A patent/CA3010915C/en active Active
- 2017-01-10 JP JP2018555315A patent/JP7311267B2/ja active Active
- 2017-01-10 EP EP17701925.4A patent/EP3402475B1/en not_active Not-in-force
- 2017-01-10 US US16/068,626 patent/US11260060B2/en active Active
-
2021
- 2021-12-03 JP JP2021197319A patent/JP7374163B2/ja active Active
-
2022
- 2022-01-14 US US17/576,197 patent/US12303516B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022019973A5 (OSRAM) | ||
| US10213420B2 (en) | Combination therapy for treatment of HBV infections | |
| US8114913B1 (en) | Systemic administration of NAC as an adjunct in the treatment of bioterror exposures such as smallpox and use in combination with DHEA for the treatment of smallpox | |
| US20210220353A1 (en) | Use of favipiravir in treatment of coronavirus infection | |
| CN103038356A (zh) | 乙酰半胱氨酸组合物及其使用方法 | |
| JP2011140521A (ja) | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 | |
| US20060189584A1 (en) | Pharmaceutical combinations | |
| JP2019501226A5 (OSRAM) | ||
| JP2009528367A (ja) | アレナウイルス感染の治療のための抗ウイルス薬剤 | |
| AU2002305952A1 (en) | Pharmaceutical combinations | |
| JPWO2020250915A5 (OSRAM) | ||
| US6281222B1 (en) | Compositions and method for treatment of acetaminophen intoxication | |
| US20250325503A1 (en) | New use of n,n-bis-2-mercaptoethyl isophthalamide | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| JPWO2020078905A5 (OSRAM) | ||
| JP2022540198A (ja) | 組合せ | |
| CN100402029C (zh) | 包含埃坡霉素衍生物和烷化剂的组合 | |
| KR20080096829A (ko) | 정맥내 항바이러스 치료 | |
| US20250197344A1 (en) | Compounds and methods for treatment of bacterial infections | |
| WO2025056747A1 (en) | Combination of a wee1 inhibitor and a pkmyt1 inhibitor | |
| CA2120234A1 (en) | 2-aminopropan-1,3-diol chemotherapeutic agents | |
| JPWO2022241134A5 (OSRAM) | ||
| HK40005150B (en) | New use of n,n-bis-2-mercaptoethyl isophthalamide | |
| HK1225968B (en) | Combination therapy for treatment of hbv infections | |
| KR20010101933A (ko) | 관상혈관 시술과 관련된 심혈관 사건의 예방 및 감소 방법 |